HuiPing Xue

HuiPing Xue

Auto-generated profile, based on publicly available information

HuiPing Xue

Department of Emergency Binzhou Center Hospital Binzhou China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2019 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
HXHuiPing Xue
HuiPing Xue
PHPing Hou
Ping Hou
YLYongNan Li
YongNan Li
XMXin'E Mao
Xin'E Mao
LWLinFeng Wu
LinFeng Wu
YLYongbing Liu
Yongbing Liu

26 October 2020 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
SLShuqing Lin
Shuqing Lin
XHXinze He
Xinze He
GZGuiliang Zhai
Guiliang Zhai
CWChenggang Wang
Chenggang Wang
HXHuiping Xue
Huiping Xue
SLShu-Feng Lin
Shu-Feng Lin
What is known and Objective This study aimed to explore the effect of sulfotanshinone sodium injection combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome (ACS). Methods We designed a prospective study and enrolled 169 patients with ACS who were admitted to our hospital as subjects. Patients treated with sulfotanshinone sodium injection combined with tirofiban (n = 99) were allocated to the research group (RG), and the remaining patients treated with tirofiban alone were allocated to the control group (n = 70; CG). The two groups were compared in terms of treatment efficacy, adverse reactions, vascular endothelial function, changes in plaque stability indicator levels, prognosis, recurrence rate, and quality of life after the treatment. Results and discussion Treatment response rate, SOD and ET‐1 levels, and quality‐of‐life score were markedly lower in RG than in CG (all P < .05). The incidence of adverse reactions; levels of CD63p, CD62p and GP IIb/IIIa; changes in plaque stability indicator levels; and recurrence rate were markedly higher in RG than in CG (all P < .05). There was no significant difference in 3‐year survival rate between the two groups (P > .05). What is new and Conclusion Compared with tirofiban alone, sulfotanshinone sodium injection combined with tirofiban had superior efficacy and safety in the treatment of ACS. It can effectively reduce recurrence rate and improve quality of life in ACS, making it a strong candidate for popular clinical application.